Rebekah Rittberg
5PUBLICATIONS
8CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jun 27, 2023
Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.Rebekah Rittberg, Bonnie Leung, Aria Shokoohi
|Dec 22, 2022
Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization.Rebekah Rittberg, Bonnie Leung, Zamzam Al-Hashami
|Nov 24, 2022
Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.Lauren Jones, Rebekah Rittberg, Bonnie Leung
|Mar 11, 2021
Canadian Cancer Centre Response to COVID-19 Pandemic: A National and Provincial Response.Rebekah Rittberg, Anmol Mann, Danielle Desautels
|Feb 04, 2021
Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an IDH1-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD.Rebekah Rittberg, Craig Harlos, Heidi Rothenmund
Pageof 1
